EGFR and non-small cell lung carcinoma: For further clarification of the disparities in clinical efficacy between dacomitinib and afatinib, Li et al. [16] demonstrated that dacomitinib exhibited a more favorable response with manageable side effects and distinct progression patterns in individuals with NSCLC bearing uncommon EGFR mutations.